Alexander J. Gilbert
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alexander J. Gilbert has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Akansha Agrawal
Division of Nephrology and Hypertension, Northwestern University Feinberg School of Medicine, Chicago, USA
1 shared publication - Catherine Wicklund
Myriad Genetics, Inc., Chicago, Illinois
1 shared publication - Debra Duquette
Medicine, Cardiology Division, Northwestern University Feinberg School of Medicine, Chicago, Illinois
1 shared publication - Elisa J. Gordon
Vanderbilt Center for Transplant Science, Vanderbilt University Medical Center, Nashville, Tennessee, USA
1 shared publication - Jessica Gacki-Smith
Center for Health Services and Outcomes Research, Northwestern University Feinberg School of Medicine, Chicago, USA
1 shared publication - John J. Friedewald
Comprehensive Transplant Center, Northwestern University, Chicago, IL, USA
1 shared publication
Latest Publications
- Open Access
- 13 February 2024
- Published by Springer Nature in Journal of Community Genetics
- Vol. 15 (2) , 205-216
Development of a culturally targeted chatbot to inform living kidney donor candidates of African ancestry about APOL1 genetic testing: a mixed methods study
Clinical chatbots are increasingly used to help integrate genetic testing into clinical contexts, but no chatbot exists for Apolipoprotein L1 (APOL1) genetic testing of living kidney donor (LKD) candidates of African ancestry. Our study aimed to culturally adapt and assess perceptions of the Gia® chatbot to help integrate APOL1 testing into LKD evaluation. Ten focus groups and post-focus group surveys were conducted with 54 LKDs, community members, and kidney transplant recipients of African ancestry. Data were analyzed through thematic analysis and descriptive statistics. Key themes about making Gia culturally targeted included ensuring: (1) transparency by providing Black LKDs’ testimonials, explaining patient privacy and confidentiality protections, and explaining how genetic testing can help LKD evaluation; (2) content is informative by educating Black LKDs about APOL1 testing instead of aiming to convince them to undergo testing, presenting statistics, and describing how genetic discrimination is legally prevented; and (3) content avoids stigma about living donation in the Black community. Most agreed Gia was neutral and unbiased (82%), trustworthy (82%), and words, phrases, and expressions were familiar to the intended audience (85%). Our culturally adapted APOL1 Gia chatbot was well regarded. Future research should assess how this chatbot could supplement provider discussion prior to genetic testing to scale APOL1 counseling and testing for LKD candidate clinical evaluation.
- 13 February 2024
- Published by Springer Nature in Journal of Community Genetics
- Vol. 15 (2) , 205-216
Open AccessDevelopment of a culturally targeted chatbot to inform living kidney donor candidates of African ancestry about APOL1 genetic testing: a mixed methods study
Clinical chatbots are increasingly used to help integrate genetic testing into clinical contexts, but no chatbot exists for Apolipoprotein L1 (APOL1) genetic testing of living kidney donor (LKD) candidates of African ancestry. Our study aimed to culturally adapt and assess perceptions of the Gia® chatbot to help integrate APOL1 testing into LKD evaluation. Ten focus groups and post-focus group surveys were conducted with 54 LKDs, community members, and kidney transplant recipients of African ancestry. Data were analyzed through thematic analysis and descriptive statistics. Key themes about making Gia culturally targeted included ensuring: (1) transparency by providing Black LKDs’ testimonials, explaining patient privacy and confidentiality protections, and explaining how genetic testing can help LKD evaluation; (2) content is informative by educating Black LKDs about APOL1 testing instead of aiming to convince them to undergo testing, presenting statistics, and describing how genetic discrimination is legally prevented; and (3) content avoids stigma about living donation in the Black community. Most agreed Gia was neutral and unbiased (82%), trustworthy (82%), and words, phrases, and expressions were familiar to the intended audience (85%). Our culturally adapted APOL1 Gia chatbot was well regarded. Future research should assess how this chatbot could supplement provider discussion prior to genetic testing to scale APOL1 counseling and testing for LKD candidate clinical evaluation.
- 1 August 2019
- Published by Wolters Kluwer Health in Current Opinion in Organ Transplantation
- Vol. 24 (4) , 365-369
Kidney transplantation across minor ABO incompatibility: the use of A2 to B transplants
Purpose of review: On 4 December 2014, the new kidney allocation system (KAS) went into effect. As part of this system, UNOS approved for the first time a national system with a specific mechanism affording priority to allocate kidneys across so-called ‘minor ABO incompatibility’ from blood group A2 donors into blood group B recipients. This significantly increased the number of such transplants done and the opportunities to learn about the specifics of such transplants. Recent findings: A2 to B transplants have been demonstrated to be well tolerated, effective, and cost-effective ways of addressing disparities in the allocation system. Further data about the use of anti-A titers and the limits to successful transplant have better defined the bounds of who can benefit from such transplants. Summary: The success thus far with A2 to B transplants should increase comfort and acceptance of the allocation policy changes and we should see further increases in centers willing to use such transplants to better address inequalities in the system.
- 1 August 2019
- Published by Wolters Kluwer Health in Current Opinion in Organ Transplantation
- Vol. 24 (4) , 365-369
Kidney transplantation across minor ABO incompatibility: the use of A2 to B transplants
Purpose of review: On 4 December 2014, the new kidney allocation system (KAS) went into effect. As part of this system, UNOS approved for the first time a national system with a specific mechanism affording priority to allocate kidneys across so-called ‘minor ABO incompatibility’ from blood group A2 donors into blood group B recipients. This significantly increased the number of such transplants done and the opportunities to learn about the specifics of such transplants. Recent findings: A2 to B transplants have been demonstrated to be well tolerated, effective, and cost-effective ways of addressing disparities in the allocation system. Further data about the use of anti-A titers and the limits to successful transplant have better defined the bounds of who can benefit from such transplants. Summary: The success thus far with A2 to B transplants should increase comfort and acceptance of the allocation policy changes and we should see further increases in centers willing to use such transplants to better address inequalities in the system.